The Prostaglandin D2 Receptor 2 industry trends have accelerated since Q4-2022, driven by a wave of targeted alliances. In March 2023, Asahi Kasei and Carna Biosciences forged a $92 m co-development pact around selective CRTH2 allosteric antagonists, combining Asahi’s lipidomics platform with Carna’s cryo-EM structural biology to shorten lead optimization by 30%. Acquisition appetite followed: Sanofi quietly acquired asthma-focused biotech Innate Immunotherapeutics in July 2023, gaining Phase II-ready CRTH2/DP1 dual antagonist SAR-447683 and expanding its immuno-inflammatory pipeline ahead of post-Xolair patent expiry. Meanwhile, Astellas launched the CRISPR-enabled DP2 knockout mouse toolkit in January 2024, offering CROs a rapid in-vivo validation model that cuts study timelines from 14 to 8 weeks. Regulatory tailwinds appeared when the EMA released a draft guidance (Dec 2023) endorsing eosinophil cationic protein as a surrogate endpoint for CRTH2-targeted asthma therapeutics, a move expected to trim Phase III costs by 15%. Venture funding has mirrored the momentum: RiverVest Ventures closed a $135 m Series B for DP2 Therapeutics in October 2023 to bankroll a US-East Coast GMP facility dedicated to CRTH2- biased agonist manufacturing. Collectively, these developments signal a shift from exploratory science to asset-centric commercialization, with allergic rhinitis and atopic dermatitis now overtaking asthma as the primary label-expansion focus for oral DP2 modulators.
